- Adrian Härri, founder, longtime CEO, and most recently CSO, has retired from operational business after 26 years and is now closely associated with the company as a delegate of the board of directors.
- Dr. Diana Hormisch and Dr. Anna Henger, longtime laboratory and department heads, have been part of the management team since the beginning of the year and are jointly responsible for the scientific management.
- Patrick Smit, currently COO, will assume the role of CEO on September 1, 2024.
- Marco Ferraro, the current CEO, is stepping down from operational business after seven years and will remain with the company as a board member.
Dittingen, July 31, 2024 – Biolytix AG is at a critical point in its history: Adrian Härri, who has served as CEO for 25 years and most recently as Chief Scientific Officer (CSO), is retiring from the operational business of Biolytix AG. Through his visionary work and the success under his leadership, he has shaped the culture and DNA of Biolytix AG. Adrian Härri has built and established Biolytix AG since its founding in 1998 into a sought-after, reliable, and flexible laboratory service provider with an international customer base. Adrian Härri will continue to be available to the company as a delegate of the board of directors and will continue to support Biolytix AG with his expertise and network in this role.
Dr. Anna Henger and Dr. Diana Hormisch have taken over the scientific management of Biolytix AG and have been part of the management team since January 1, 2024. Both have over 25 years of professional experience and have been with Biolytix as laboratory and scientific department heads for 15 years and are well-known to customers. Dr. Anna Henger and Dr. Diana Hormisch have been crucial to the scientific and operational development of Biolytix AG in recent years and have significantly contributed to the company’s success.
Patrick Smit brings extensive international experience in sales and business development in the life sciences and GxP sectors. He has worked for two well-known multinational companies in the past 20 years that hold leading market positions in the fields of isolator technology, automation, and sterile liquid applications for pharmaceutical and biotech companies. Patrick Smit will assume the role of CEO from Marco Ferraro on September 1, 2024. As CEO, he will form the new leadership team of Biolytix AG together with Dr. Henger and Dr. Hormisch.
After more than seven years with the company, Marco Ferraro, the current CEO, will leave the operational business at the end of August 2024. Marco has decided to relinquish the operational responsibility of Biolytix AG for personal reasons. During his tenure, he updated the processes and IT infrastructure and significantly contributed to the company’s success in recent years, during which Biolytix AG was a successful provider in the Corona testing market. Marco Ferraro will continue to support Biolytix AG strategically as a board member.
Christoph Keigel, co-founder and chairman of the board of directors of Biolytix AG, commented on this transition: “Adrian’s vision and passionate commitment as an entrepreneur and scientist have made Biolytix AG what it is today: a leading Swiss company for molecular and microbiological analyses. His decision to retire from operational business marks the end of an era after 26 years, but not the end of his contributions to our company. We are grateful that he remains an integral part of Biolytix AG as a delegate of the board of directors and continues to serve the company in this capacity. His knowledge and experience are invaluable resources that will continue to shape the future path of Biolytix AG together with a highly qualified and motivated leadership team.”
Company Profile
Biolytix AG is a leading company for molecular and microbiological analyses based in Dittingen, Canton Basel-Landschaft, Switzerland.
Biolytix AG was founded in 1998 with the goal of becoming a leading provider in analytics using real-time PCR.
Today, the company serves national and international customers as a service laboratory and aims for a leading position in Europe with its core competencies in micro- and molecular biological analytics in the areas of sterile and product testing, food and agro diagnostics, hygiene and microbiology, contract research for life sciences and pharmaceutical companies, and allergen analysis.
The high quality standards of Biolytix AG have enabled its customers to professionally meet their requirements for process and product safety for over 25 years.
Biolytix AG is characterized by high competence and offers customer-oriented solutions of comprehensive quality with ISO 17025 accreditation.
Contact for further information:
Adrian Härri
Delegate of the Board of Directors
Phone: 061 725 20 70
Email: adrian.haerri@biolytix.ch
Patrick Smit
CEO
Phone: 061 725 20 70
Email: patrick.smit@biolytix.ch
